江苏浩欧博生物医药股份有限公司2025年第三次临时股东大会决议公告

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders of Jiangsu Haooubo Biopharmaceutical Co., Ltd. held on September 25, 2025, which included the approval of key proposals [1][4]. - The meeting was legally convened and conducted, with all procedures in compliance with the Company Law and the company's articles of association [2][5]. - All directors, supervisors, and the board secretary attended the meeting, confirming full participation from the company's leadership [3]. Group 2 - Two main proposals were approved during the meeting: the adjustment of the 2025 annual director remuneration and the purchase of liability insurance for directors, supervisors, and senior management [4]. - The voting process was conducted through a combination of on-site and online voting, ensuring that the resolutions were passed with more than half of the valid voting rights represented [5]. - The meeting was witnessed by legal representatives from Guohao Law Firm (Shanghai), who confirmed the legality and validity of the meeting's procedures and voting results [5].